BioNTech SE (BNTX.xnas)

BioNTech SE (BNTX.xnas)


Charts by TradingView

Pricing is indicative. Past performance is not a reliable indicator of future results. Log in to see latest markets data.

BioNTech SE (BNTX.xnas) Profile

BioNTech SE (BNTX.xnas) is a biotechnology company developing and commercialising immunotherapies for cancer and other infectious diseases headquartered in Mainz, Germany. BioNTech develops pharmaceutical product candidates for advanced melanoma, prostate cancer, triple-negative breast cancer, ovarian cancer, cell lung cancer and neoantigen-specific immunotherapies, such as Autogene cevumeran. BioNTech along with Pfizer, developed the RNA vaccine BNT 162b2 to prevent COVID-19 infections, the first mRNA vaccine ever authorized and approved later in the United States, Canada, and Switzerland. BioNTech operates in Germany, San Diego, Cambridge, and Massachusetts, with 8 offices in 2 countries. The company employs 1323 people and has a market capitalisation of $73.41B (USD) as of December 2021. BioNTech stock (BNTX.xnas) is listed as American Depository Shares (ADS) on the NASDAQ Global Select Market. BioNTech plans to open its Asia headquarters in Singapore and a vaccine manufacturing plant with support from the Singapore Economic Development Board in 2023. BioNTech aim to produce hundreds of millions of doses of mRNA vaccines per year. In November 2021, BioNTech and Pfizer announced that a three-shot course of their COVID-19 vaccine was able to neutralise the new Omicron variant, and they could deliver an Omicron-based vaccine in March 2022 if needed.

Holding cost
Long
-5%
Short
-2.5%
Trading hours in US Eastern Time
Fri
16:30-23:00
Mon
16:30-23:00
Tue
16:30-23:00
Wed
16:30-23:00
Thu
16:30-23:00
Sun
Closed
Sat
Closed

Start Trading BioNTech SE (BNTX.xnas)
with a Market Leader Today

Share CFD Trading FAQ

Each investor owning shares of a company is also owning fragments of the company. A quite simple way to explain what a stock is is basically when a company divides itself into several shares and then it makes a part of these equities available to the public, at a price. Each investor owning shares of a company is owning fragments of the company.

While shares represent units of ownership within a company Contracts for Difference (CFDs) allow traders to speculate on the future share price fluctuations of an underlying asset. Thus when trading CFDs traders do not physically own the underlying asset. CFDs are available for a range of underlying assets, such as shares, commodities, and foreign exchange, and indices.

6 Reasons to Trade Share
CFDs with FP Markets

An Australian-regulated
forex & CFD broker

Go Long or Short

Increase your ability to profit in all market conditions Leverage options up to 20:1

Direct Market Access (DMA) Execution

Real-time, transparent share prices Control, Functionality and deep liquidity Full Market depth & see your orders in the queue

Advanced Platforms
& Technology

MT4, MT5, Webtrader & Iress with superior client portal

24/5 Multilingual
Customer Support

Award winning support & personal account managers

Global Exposure

Low margins and competitive commission +10,000 products on global stocks across 4 continents

Earn Dividends

On long positions No ownership of physical shares necessary

Start Trading
in Minutes

Open an account now

bullet Access 10,000+ financial instruments
bullet Auto open & close positions
bullet News & economic calendar
bullet Technical indicators & charts
bullet Many more tools included

By supplying your email you agree to FP Markets privacy policy and receive future marketing materials from FP Markets. You can unsubscribe at any time.





Get instant Updates in Telegram
Sitemap | © FP Markets 2022